ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 481

Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice

Takaichi Okano1, Jun Saegusa2, Keisuke Nishimura3, Yo Ueda4, Sho Sendo2, Soshi Takahashi5, Kengo Akashi3, Akira Onishi6 and Akio Morinobu2, 1Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Department of Rheumatology, Kobe University Hospital, Kobe, Japan, 4Kobe University Graduate School of Medicine, Kobe, Japan, 5Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department for Rheumatology, Kobe University Hospital, Kobe, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Arthritis, dendritic cells and metabolism, T cells, T-Regulatory Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies have shown that cellular metabolism plays an important role in regulating immune cell function. In the process of cell differentiation, both interleukin-17-producing helper T (Th17) cells and dendritic cells (DCs) show increase of glycolytic activity by upregulating glycolytic enzymes, such as hexokinase-2 (HK2). Blocking glycolysis by 2-deoxyglucose has recently been demonstrated to inhibits Th17 cell differentiation while promotes regulatory T (Treg) cell generation, and then ameliorates experimental autoimmune encephalitis model. In addition, inhibition of glycolysis by 2-deoxyglucose has been reported to suppress activation of DCs. The aim of this study is to verify the effect of 3-bromopyruvate (BrPA), a specific inhibitor of HK2, on the differentiation and function of immune cells and on experimental arthritis in SKG mice.

Methods: Synovium from rheumatoid arthritis (RA) patients was stained by anti-HK2 antibody. Arthritis was induced in SKG mice by Zymosan A (ZyA) injection. BrPA (5mg/kg) was administered subcutaneously once daily. CD4+ T cells from spleens of unimmunized SKG mice were cultured with anti-CD3/anti-CD28, anti-IFN-γ, anti-IL-4, IL-6, TGF-β, IL-2, with and without BrPA for 5 days, and then analyzed by flow cytometry. Bone marrow (BM) cells from unimmunized SKG mice were cultured with GM-CSF and IL-4 (for 3 days), and with lipopolysaccharide (for 1 day) with and without BrPA, and then analyzed by flow cytometry.

Results: Immunohistochemistry revealed that HK2 expressing lymphocytes were increased in RA synovium. Treatment with BrPA significantly ameliorated arthritis of SKG mice (Figure). Histological scores of arthritis in BrPA-treated mice significantly were decreased compared to those of the control mice. Significant increase of Treg cells, decrease of Th17 cells, and decrease of CD40+CD86+CD11b+CD11c+ (activated) DCs were observed in the spleens from BrPA-treated SKG mice. In vitro, BrPA facilitated the differentiation of Treg cells, while it inhibited the development of Th17 cells. In addition, treatment of BM cells with BrPA reduced the proportion of activated DCs and inhibited the production of TNF-α, IL-6.

Conclusion: BrPA ameliorates autoimmune arthritis in SKG mice by facilitating the differentiation of Treg cells, and inhibiting the development of Th17 cells and activation of DCs.


Disclosure: T. Okano, None; J. Saegusa, None; K. Nishimura, None; Y. Ueda, None; S. Sendo, None; S. Takahashi, None; K. Akashi, None; A. Onishi, None; A. Morinobu, None.

To cite this abstract in AMA style:

Okano T, Saegusa J, Nishimura K, Ueda Y, Sendo S, Takahashi S, Akashi K, Onishi A, Morinobu A. Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dual-effect-of-3-bromopyruvate-on-both-th17-and-treg-cell-differentiation-and-dendritic-cell-activation-ameliorates-autoimmune-arthritis-in-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dual-effect-of-3-bromopyruvate-on-both-th17-and-treg-cell-differentiation-and-dendritic-cell-activation-ameliorates-autoimmune-arthritis-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology